Indimitecan

N/A

Report date: 2025/03/26 16:47:38
NME

Base Information

Drug NameIndimitecan
Drug Alias NameLMP-776NSC-725776
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstitutePurdue University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteGibson Oncology LLC
Active IndicationsN/A
Inactive IndicationsLymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A